RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.
A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究结果确定了 GPR35 是一种新的癌细胞内在的免疫逃逸和免疫治疗耐药驱动因子,将其定位为一个有前景的治疗靶点,可使“冷”CRC 肿瘤对免疫检查点阻断敏感。
结直肠癌(CRC)仍然是全球癌症死亡的主要原因,其治疗结果在很大程度上依赖于肿瘤微环境(TME)。尽管免疫疗法已经彻底改变了特定亚群患者的治疗,但大多数患者中驱动免疫逃逸的机制仍不清楚。
在本研究中,我们通过整合多队列scRNA-seq数据,构建了CRC TME的全面单细胞图谱。
通过非负矩阵分解(NMF),我们识别出九个肿瘤内异质性元程序(MPs),其中MP8与M2巨噬细胞活化稳健相关。高维WGCNA进一步确定GPR35为MP8相关基因网络中的主调控因子。跨四个独立队列的临床分析验证了GPR35是预后不良的显著预测因子。在功能上,体外敲低GPR35显著损害了CRC细胞的增殖、迁移和侵袭。在机制上,GPR35高表达 orchestrated 一个免疫排斥微环境,其特征为细胞毒性T细胞和NK细胞募集减少,但矛盾的是免疫检查点表达升高。此外,GPR35表达与八个已确立的免疫治疗应答特征负相关,并与侵袭性突变景观相关。
In this study, we constructed a comprehensive single-cell atlas of the CRC TME by integrating multi-cohort scRNA-seq data.
Through non-negative matrix factorization (NMF), we identified nine intratumoral heterogeneity meta-programs (MPs), among which MP8 was robustly linked to M2 macrophage activation. High-dimensional WGCNA further pinpointed GPR35 as a master regulator within the MP8-associated gene network. Clinical analysis across four independent cohorts validated GPR35 as a significant predictor of poor prognosis. Functionally, GPR35 knockdown in vitro markedly impaired CRC cell proliferation, migration, and invasion. Mechanistically, high GPR35 expression orchestrated an immune-excluded microenvironment characterized by diminished cytotoxic T cell and NK cell recruitment, yet paradoxically elevated immune checkpoint expression. Furthermore, GPR35 expression was negatively correlated with eight established immunotherapy response signatures and associated with aggressive mutational landscapes. DISCUSSION: Collectively, our findings identify GPR35 as a novel cancer cell-intrinsic driver of immune evasion and immunotherapy resistance, positioning it as a promising therapeutic target to sensitize "cold" CRC tumors to immune checkpoint blockade.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。